Nitrome’s $38 Million Series A Financing

Wilson Sonsini Goodrich & Rosati represented Nitrome in the transaction.

Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, announced that it has closed a Series A financing of $38 million co-led by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie’s corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments. Henrijette Richter, Ph.D., Managing Partner of Sofinnova Partners, Margarita Chavez, Managing Director of AbbVie Ventures and Jonathan Behr, Ph.D., Partner of the Dementia Discovery Fund, will join Nitrome’s Board of Directors.

The financing is intended to support the advancement of Nitrome’s lead program targeting Parkinson’s Disease toward human clinical proof of concept studies and to explore the application of the company’s platform technology in other age-related disorders.

Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease.

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences.

AbbVie Ventures is the corporate venture capital group of AbbVie.

The Wilson Sonsini team that advised Nitrome Biosciences in the transaction included Elton Satusky (Picture), Brian Appel, Patricia Swen, and Lenka Schvaigerova.

Involved fees earner: Brian Appel – Wilson Sonsini Goodrich & Rosati; Elton Satusky – Wilson Sonsini Goodrich & Rosati; Patricia Swen – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Nitrome Biosciences;

Author: Ambrogio Visconti